The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
about
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityMechanisms of phthalate ester toxicity in the female reproductive systemThe effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot studyEffect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studiesEvidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndromeShould all women with PCOS be treated for insulin resistance?Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecologyPolycystic ovary syndrome: a risk factor for cardiovascular disease?Sequence variation in PPARG may underlie differential response to troglitazone.The long term health consequences of polycystic ovary syndrome.Polycystic ovary syndrome and its developmental origins.A variant in the fibrillin-3 gene is associated with TGF-β and inhibin B levels in women with polycystic ovary syndrome.Similar causes of various reproductive disorders in early lifeObstructive sleep apnea and metabolic dysfunction in polycystic ovary syndromeThe influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies.Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome.Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization.State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).An Association Study between INSR/NsiI (rs2059806) and INSR/PmlI (rs1799817) SNPs in Women with Polycystic Ovary Syndrome from West Azerbaijan Province, IranDrospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatinInsulin resistant states and insulin signaling.Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndromeInsulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS).The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma.Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome.Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice.Thiazolidinediones for treatment of polycystic ovary syndrome.The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatmentRole of metformin in the management of polycystic ovary syndrome.Polycystic Ovary Syndrome and Obstructive Sleep ApneaEvidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women.Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.Peroxisome proliferator-activated receptors: new players in the field of reproduction.Targets to treat metabolic syndrome in polycystic ovary syndromeGenetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review.Menstrual health and the metabolic syndrome in adolescents.Activation of PPARγ by Rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats.
P2860
Q24240654-326C4A72-F7D8-441D-A0F4-8BADF6F12A3FQ24529989-8D3EA217-E102-4C3B-AE5B-0B3DF6918AEEQ25257236-B76E7921-68D0-4E92-B295-755110861BBBQ28575457-CF3A9778-8572-4C84-A480-3BE60E71E59DQ30303066-1BD7E8ED-41DD-493E-B063-577B2034DC99Q30423117-E6EABD11-2CE0-40E5-9FD8-386CD536EDC2Q33569169-5E6E47D7-D548-4879-8D80-E427465B1BD1Q33791299-88F26B29-2C20-4E6E-B6A9-AA77A4621777Q33823437-4CFC67A7-22EF-43BF-AEB4-3437059915F3Q34072562-AD34E330-51F4-4854-B4B6-76731F1F725AQ34105196-73687C00-1DEB-4FBE-B321-AF2D05584055Q34109499-33A8C54A-CEB6-464C-92DB-2FAE1F84A6B2Q34338946-2644AE4A-BB8A-4123-A39E-55165276C272Q34394422-9289924A-46B3-4CF6-B845-4946C15F1DB7Q34536081-760C41F9-6E4E-4193-A34F-B3868A9F5A97Q34544099-6EFD59EE-37BA-4985-909A-ECBC36DD74C9Q34758467-7C7449C5-A84D-426B-877B-9E2E1C8A13A1Q34827095-463F64E0-DA04-4110-B9C1-C4D8600A878BQ35233754-CEDA55EA-58B4-46F6-A0D1-A01DD04E2BFBQ35276405-C695AD9B-49FF-4801-AD14-114BDC37E8A0Q35468539-C9271B57-7DF1-4924-8425-BBC06518A88DQ35556131-7BCFB9BE-7181-46B5-A6C5-3842F8B7E076Q35576057-6AC4E82C-3D60-4D17-859A-B25C133B98C1Q35597070-F463A70C-6AC9-4773-8061-2F02BD1BAC4CQ35599772-264B758F-A3BA-44AA-8AD2-015E7496BF86Q35606054-2310B72A-5622-4ACB-B192-DC42F0DE9340Q35676497-6F33DB73-867A-4B9F-A697-7CF1F74F306FQ35690925-540FBBBA-C154-4118-B689-E547C0F90744Q35803853-8A34C521-0D2A-4761-9EE3-C9D4216D6A58Q36070934-5E39B394-EB5A-4D27-A152-D0E251C46B2DQ36269492-8B31FE00-FF8B-4B49-B563-0CB42B65016FQ36329913-0F0B2655-CCFB-49BE-A28D-C9E41751D3C5Q36666354-CF871E00-9781-44CA-B4ED-C44CA23B6FC8Q36732717-F30ACC0A-41D1-461B-BECB-9CD384647075Q36758555-884D76F1-EB69-45D0-A982-CB82A2872BEBQ36903108-7CF0D00A-0D3A-4194-92F3-DDF653C634A1Q36943683-29B4DFB2-0C11-4BB5-93B8-08F7298E0925Q37049974-CC0404D6-51F0-4712-AF6D-EEE72314B00CQ37198401-82BC6BE5-BAC7-4EAC-A648-58715B253DCCQ37226962-D9949A51-1AE7-46D2-A0AC-9734436F658D
P2860
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@en
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@nl
type
label
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@en
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@nl
prefLabel
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@en
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@nl
P2093
P356
P1476
The insulin-sensitizing agent ...... the polycystic ovary syndrome.
@en
P2093
P304
P356
10.1210/JC.81.9.3299
P407
P577
1996-09-01T00:00:00Z